Fuji Keizai: Japan Pharma Capex Up 50% to 946 Billion Yen
KEY POINTSFuji Keizai survey shows 25 Japanese drugmakers’ capital spending reaches 946 billion yen in 2025, about 50%…
EirGenix Advances into CPHI Japan, Capitalizing on Market Trends to Deepen Its Strategic Footprint in Japan
TOKYO, April 29, 2026 /PRNewswire/ — As the global biopharmaceutical industry undergoes rapid restructuring, two powerful forces—policy evolution and…